Medanta & Roentgen-BLK acquires CyberKnife VSI System to ensure better cancer treatment
Indian hospitals Medanta and the Roentgen-BLK recently acquired and started treating cancer patients with CyberKnife VSI System, a premier solution for full-body radiosurgery developed by Accuray Incorporated marking the technologies foray into the Indian market. Both the hospitals can now provide patients treatment with the CyberKnife System and expand the patient population that can now benefit from CyberKnife radiosurgery and stereotactic body radiation therapy (SBRT) in the region.
Building upon the foundation of accuracy and precision in radiosurgery, the CyberKnife System extends these benefits to fractionated high precision radiation therapy with robotic intensity-modulated radiotherapy (IMRT) that can be delivered anywhere in the body, including intracranial, head and neck, spine, lung, liver and prostate. The enhanced spectrum of treatment options allows for more customised treatment plans based on patient-specific situations and conditions, such as patients requiring re-irradiation of previously treated area, or patients requiring partial breast irradiation. With more than 700 hundred peer-reviewed publications and a rapidly increasing number of treated patients, the growing community of CyberKnife users is discovering more applications that can be helped by the technological edge that the CyberKnife System provides.
“The CyberKnife System is increasingly being used as an alternative to conventional radiation therapy in situations where its targeting accuracy allows a shorter and more intense course of radiation, including radiosurgery for brain tumours. We are pleased to have introduced this innovative technology at Medanta and look forward to witnessing the benefits that the System offers, including real-time tracking with automatic correction of tumours that move throughout the body. The CyberKnife System comes as a significant development in cancer therapy for patients as well as doctors as it offer the most precise treatment option for a wide range of patients,” said Naresh Trehan, chairman and managing director of Medanta.
“We are always refining radiation oncology treatment methods to deliver the highest-quality patient care possible, while working to also reduce or eliminate the side effects that accompany radiation treatment. Using the CyberKnife System allows our radiation oncologists to provide the most up-to-date technology available to accurately target tumours, deliver treatments with pinpoint accuracy and ensure that tumours get the most effective ablative dose while healthy tissues and critical structures are spared,” said Praneet Kumar, CEO of Roentgen-BLK Radiation Oncology Center.